Article
Gastric cancer combination therapy by siRNA-mediated NRF2 silencing and paclitaxel
2023-06-28
Abstract excerpt
<h4>Background: </h4> Gastric cancer (GC) is a highly chemoresistant malignancy with a poor prognosis. Paclitaxel's low response rate as second-line chemotherapy for advanced GC has prompted intensive research into its molecular basis and prospective targeted therapies to enhance its therapeutic efficacy. The objective of this study was to investigate the synergistic effects of NRF2 silencing in combination with p...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 6de0ff67-c19d-5322-b95b-181e7b18cb74
- DOI
- 10.21203/rs.3.rs-3095925/v1
